RT Journal Article
T1 Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial
A1 Pulido, Federico
A1 Ribera, Esteban
A1 Lagarde, Maria
A1 Perez-Valero, Ignacio
A1 Palacios, Rosario
A1 Iribarren, Jose A.
A1 Payeras, Antoni
A1 Domingo, Pere
A1 Sanz, Jose
A1 Cervero, Miguel
A1 Curran, Adrian
A1 Rodriguez-Gomez, Francisco J.
A1 Tellez, Maria J.
A1 Ryan, Pablo
A1 Barrufet, Pilar
A1 Knobel, Hernando
A1 Rivero, Antonio
A1 Alejos, Belen
A1 Yllescas, Maria
A1 Arribas, Jose R.
A1 DUAL-GESIDA-8014-RIS-EST45 Study G, 
K1 darunavir/ritonavir
K1 lamivudine
K1 switch
K1 dual therapy
K1 Non-inferiority trial
K1 Reverse-transcriptase inhibitor
K1 Virologically stable patients
K1 Boosted protease inhibitor
K1 Antiretroviral therapy
K1 Coformulated elvitegravir
K1 2 nucleos(t)ides
K1 Phase 3b
K1 Simplification
K1 Hiv
AB Background. Our objective was to assess the therapeutic noninferiority of dual therapy with darunavir/ritonavir and lamivudine compared to triple therapy with darunavir/ritonavir plus 2 nucleos(t)ides for maintenance of human immunodeficiency virus type 1 (HIV-1) suppression.Methods. This was a multicenter, open-label, noninferiority trial (margin 12%). Patients with HIV-1 RNA
PB Oxford univ press inc
SN 1058-4838
YR 2017
FD 2017-12-15
LK http://hdl.handle.net/10668/18942
UL http://hdl.handle.net/10668/18942
LA en
DS RISalud
RD Apr 12, 2025